Article

SARS-CoV-2 oral tablet vaccination induces neutralizing mucosal IgA in a phase 1 open label trial

2022-07-19

Abstract excerpt

<h4>Background</h4> Despite the plethora of efficacious vaccines to the initial Wuhan strain of SARS-CoV-2, these do not induce robust mucosal immunity, offering limited protection against breakthrough infection and replication in the respiratory tract. The mucosa is the first line of defense, therefore a vaccine that induces a mucosal IgA response could be an important strategy in curbing the global pandemic. <h4...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 40a2d77a-f9fc-5241-893b-fc543cd09f2b
DOI: 10.1101/2022.07.16.22277601

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

SARS-CoV-2 oral tablet vaccination induces neutralizing mucosal IgA in a phase 1 open label trialDOI 10.1101/2022.07.16.22277601Read

Long-term systemic and mucosal SARS-CoV-2 IgA response and its association with persistent smell and taste disordersSemantic proximity Read

Phase 1 Study of Safety, Reactogenicity, and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate Administered as Inhalation Boost in SARS-CoV-2 Immunized AdultsSemantic proximity Read

Detection of anti–SARS-CoV-2 mucosal IgA in clinical saliva samples after a dose of Novavax COVID-19 vaccineSemantic proximity Read

Mucosal Immunization of Cynomolgus Macaques with Adenoviral Vector Vaccine Elicits Neutralizing Nasal and Serum Antibody to Several SARS-CoV-2 VariantsSemantic proximity Read

Single-dose respiratory mucosal delivery of next-generation viral-vectored COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2Semantic proximity Read

Mucosal and systemic responses to SARS-CoV-2 vaccination in infection naïve and experienced individualsSemantic proximity Read

Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19Semantic proximity Read

Mucosal Immune Response in BNT162b2 COVID-19 Vaccine RecipientsSemantic proximity Read

Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variantsSemantic proximity Read

Inhalable SARS-CoV-2 vaccine for single-dose dry powder aerosol immunizationSemantic proximity Read

Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2Semantic proximity Read

Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccineSemantic proximity Read